NIFTY 50
26,046.95 (0.57%)
NIFTY IT
38,274.75 (0.47%)
NIFTY AUTO
27,820.85 (0.58%)
NIFTY FINANCIAL SERVICES
27,672.60 (0.40%)
NIFTY BANK
59,389.95 (0.30%)
NIFTY REALTY
886.55 (1.53%)
NIFTY ENERGY
35,039.85 (0.83%)
NIFTY METAL
10,536.45 (2.63%)
NIFTY FMCG
54,490.80 (-0.24%)
NIFTY HEALTH CARE
14,753.85 (0.26%)
NIFTY PHARMA
22,808.70 (0.11%)
NIFTY MEDIA
22,808.70 (0.11%)
Platforms
Webinars
Insights
Research
Videos
Markets
Equity
Derivatives
IPO
Other Markets
Corporate Information
Pricing
Support
Login
Login to Trade
Login to Reports
Open an Account
Home
Platform
Insights
Research
Markets
Pricing
Support
Login
Open an Account
Trend of Stock Market
A trend is the broad upward or downward movement of a stock's price over time
Forthcoming IPO
Open Issues
Closed Issue
Top Gainers / Losers
52 Weeks High/ Low
Value / Volume Toppers
Get Quotes
Nifty Futures
Top Traded Quantity
Top Traded Value
Derivative Summary
Daily Settlement Price
List Of Underlying
Put Call Ratio
FII Statistics
Most Active Contract
All Index Futures
Top Gainers
Top Losers
Highest In OI
Lowest In OI
Increase In OI
Decrease In OI
Most Active Calls
Most Active Put
Top Gainers
Top Losers
Highest In OI
Lowest In OI
Increase In OI
Decrease In OI
Forthcoming Issues
Open Issues
Closed Issue
World Indices
ADR Prices
MF Investment
FII Investment
Get Quotes
Company Snapshot
Company Background
Board of Directors
Directors Reports
Profit & Loss
Balance Sheet
Quarterly Results
Shareholding Pattern
Key Financial Ratios
Mutual Fund Holdings
Peer Comparison
Technical Chart
Company News
Change Company Name
Sun Pharmaceutical Industries Ltd
Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
524715
ISIN Demat
INE044A01036
Book Value
99.25
NSE Symbol
SUNPHARMA
Dividend Yield (%)
0.89
Market Cap (
₹
Cr.)
430,512.67
P/E
92.11
EPS
19.48
Face Value
1
Date
Headline
01-Dec-25
Sun Pharma launches innovative drug ILUMYA (Tildrakizumab) in India
15-Oct-25
Sun Pharmaceuticals Industries to conduct board meeting
21-Jul-25
Sun Pharma announces top-line results of tildrakizumab 100 mg Phase 3 studies
14-Jul-25
Sun Pharmaceutical Industries launches LEQSELVI™ (deuruxolitinib) 8 mg tablets in United States
12-Jul-25
Sun Pharmaceuticals Industries to table results
14-Jun-25
Sun Pharma updates on US FDA inspection
23-May-25
Board of Sun Pharmaceutical Industries appoints director
22-May-25
Board of Sun Pharmaceuticals Industries recommends final dividend
12-May-25
Sun Pharmaceuticals Industries announces board meeting date
24-Apr-25
Sun Pharma and Israel-based Moebius Medical publish two articles on MM-II
Prev
1
2
3
Next